We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Dave Sebastian
Gilead Sciences Inc. and Galapagos NV said their arthritis drug got a scientific recommendation from the European Medicines Agency to grant marketing authorization in Europe.
The recommendation comes after phase 2 and 3 studies for the drug, Jyseleca, met primary endpoints, the companies said Friday.
The European Commission will now review the recommendation, with an expected decision in the third quarter, the companies said. If authorized, the company can market the drug in the European Union's 27 countries.
The companies said the once-daily filgotinib had a consistent clinical safety profile when applied as monotherapy or in combination with methotrexate during the trials.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
July 24, 2020 08:59 ET (12:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
